Skip Navigation
Menu
ACP Journal Club |18 July 2017

Review: In chronic hepatitis C virus infection, oral direct-acting antivirals have high sustained virologic response

Henry S. Sacks, PhD, MD

Article, Author, and Disclosure Information
FULL TEXT
Falade-Nwulia O, Suarez-Cuervo C, Nelson DR, et al. Oral direct-acting agent therapy for hepatitis C virus infection: a systematic review. Ann Intern Med. 2017;166:637-48. 28319996

GIM/FP/GP:

Infectious Disease:

In patients with chronic hepatitis C virus (HCV) infection, what are the efficacy and safety of oral direct-acting antiviral (DAA) regimens?
Included English-language studies assessed interferon-free treatment regimens of ≥ 2 DAAs that were approved by the US Food and Drug Administration and lasted ≥ 8 weeks in adults with chronic HCV infection, regardless of cirrhosis, HIV, or liver transplantation status. DAA combinations included inhibitors of HCV NS3 protease (grazoprevir, paritaprevir, and simeprevir), NS5A (daclatasvir, elbasvir, ledipasvir, ombitasvir, and velpatasvir), and NS5B polymerase (sofosbuvir and dasabuvir), with or without oral antiviral ribavirin. Outcomes were sustained virologic response (SVR) and adverse events.
FULL TEXT
PDF
Not Available
Citations
Citation

Sacks HS. Review: In chronic hepatitis C virus infection, oral direct-acting antivirals have high sustained virologic response. Ann Intern Med. ;167:JC3. doi: 10.7326/ACPJC-2017-167-2-003

Download citation file:

© 2019

×
Permissions

Published: Ann Intern Med. 2017;167(2):JC3.

DOI: 10.7326/ACPJC-2017-167-2-003

©
2017 American College of Physicians
2 Citations

Related Articles
Remission of Psoriasis After Treatment of Chronic Hepatitis C Virus Infection With Direct-Acting Antivirals
Annals of Internal Medicine; 168 (9): 678-680
Hepatitis B Virus Reactivation Associated With Direct-Acting Antiviral Therapy for Chronic Hepatitis C Virus: A Review of Cases Reported to the U.S. Food and Drug Administration Adverse Event Reporting System
Annals of Internal Medicine; 166 (11): 792-798
Annals for Educators - 6 June 2017
Annals of Internal Medicine; 166 (11): ED11
Sustained Virologic Response and Clinical Outcomes in Patients with Chronic Hepatitis C and Advanced Fibrosis
Annals of Internal Medicine; 147 (10): 677-684
View MoreView Less

Journal Club
Review: Oral antiviral drugs reduce clinical recurrence in recurrent genital herpes
Annals of Internal Medicine; 162 (4): JC7
Review: Telaprevir, boceprevir, simeprevir, or sofosbuvir improves response in HCV type 1
Annals of Internal Medicine; 161 (10): JC11
Review: Neuraminidase inhibitors reduce symptomatic influenza; oseltamivir does not reduce hospitalizations
Annals of Internal Medicine; 161 (8): JC2
Telaprevir combination therapy induced a sustained virologic response in nonresponsive chronic HCV infection
Annals of Internal Medicine; 153 (4): JC2-7
View MoreView Less

Related Point of Care
Hepatitis C Virus
Annals of Internal Medicine; 165 (5): ITC33-ITC48
Influenza
Annals of Internal Medicine; 167 (5): ITC33-ITC48
View MoreView Less

Related Topics
Gastroenterology/Hepatology
Infectious Disease
Liver Disease
Viral Hepatitis

Gastroenterology/Hepatology, Infectious Disease, Liver Disease, Viral Hepatitis.

PubMed Articles
Synthesis and structure-activity relationship studies of water-soluble β-cyclodextrin-glycyrrhetinic acid conjugates as potential anti-influenza virus agents.
Eur J Med Chem 2019;
Natural Products for Drug Discovery: Discovery of Gramines as Novel Agents against a Plant Virus.
J Agric Food Chem 2019.
View More

Results provided by: PubMed

CONTINUE WITH LIMITED ACCESS
Annals of Internal Medicine
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
acp link acp
silverchair link silverchair

Copyright © 2019 American College of Physicians. All Rights Reserved.

Print ISSN: 0003-4819 | Online ISSN: 1539-3704

Privacy Policy

|

Conditions of Use

This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy. | Accept
×

You need a subscription to this content to use this feature.

×
PDF Downloads Require Access to the Full Article.
Annals of Internal Medicine
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
Access to this Free Content Requires Users to be Registered and Logged In. Please Choose One of the Following Options
Annals of Internal Medicine
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×